Top 5 Stocks to Buy Now
→ Your book attached (From Profits Run) (Ad)tc pixel Free JSPR Stock Alerts

Jasper Therapeutics (JSPR) Competitors

Jasper Therapeutics logo
$0.35 -0.10 (-21.82%)
Closing price 04:00 PM Eastern
Extended Trading
$0.34 -0.01 (-1.79%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

JSPR vs. KALA, MREO, ACTU, INCR, and IXHL

Should you buy Jasper Therapeutics stock or one of its competitors? MarketBeat compares Jasper Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jasper Therapeutics include KALA BIO (KALA), Mereo BioPharma Group (MREO), Actuate Therapeutics (ACTU), InterCure (INCR), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.

How does Jasper Therapeutics compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

KALA BIO currently has a consensus price target of $1,018.75, suggesting a potential upside of 40,326.59%. Jasper Therapeutics has a consensus price target of $13.14, suggesting a potential upside of 3,754.21%. Given KALA BIO's higher probable upside, research analysts clearly believe KALA BIO is more favorable than Jasper Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KALA BIO
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Jasper Therapeutics
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 2.3% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Jasper Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KALA BION/AN/A-$26.98M-$96.14N/A
Jasper TherapeuticsN/AN/A-$75.80M-$3.23N/A

Jasper Therapeutics' return on equity of -613.51% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
KALA BION/A -1,336.10% -94.85%
Jasper Therapeutics N/A -613.51%-162.52%

In the previous week, KALA BIO and KALA BIO both had 1 articles in the media. KALA BIO's average media sentiment score of 1.87 equaled Jasper Therapeutics'average media sentiment score.

Company Overall Sentiment
KALA BIO Very Positive
Jasper Therapeutics Very Positive

KALA BIO has a beta of -2.4, suggesting that its stock price is 340% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3, suggesting that its stock price is 200% more volatile than the broader market.

Summary

Jasper Therapeutics beats KALA BIO on 7 of the 11 factors compared between the two stocks.

How does Jasper Therapeutics compare to Mereo BioPharma Group?

Jasper Therapeutics (NASDAQ:JSPR) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Jasper Therapeutics has a beta of 3, suggesting that its stock price is 200% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Mereo BioPharma Group has higher revenue and earnings than Jasper Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/A-$75.80M-$3.23N/A
Mereo BioPharma Group$500K94.68-$41.88M-$0.05N/A

In the previous week, Mereo BioPharma Group had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 2 mentions for Mereo BioPharma Group and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.87 beat Mereo BioPharma Group's score of 1.44 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Jasper Therapeutics Very Positive
Mereo BioPharma Group Positive

Mereo BioPharma Group's return on equity of -81.28% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A -613.51% -162.52%
Mereo BioPharma Group N/A -81.28%-70.45%

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Jasper Therapeutics presently has a consensus target price of $13.14, suggesting a potential upside of 3,754.21%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 995.75%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than Mereo BioPharma Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jasper Therapeutics
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Mereo BioPharma Group
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Jasper Therapeutics and Mereo BioPharma Group tied by winning 7 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Actuate Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Jasper Therapeutics has a beta of 3, indicating that its stock price is 200% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Jasper Therapeutics currently has a consensus price target of $13.14, suggesting a potential upside of 3,754.21%. Actuate Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 941.67%. Given Jasper Therapeutics' higher probable upside, equities analysts plainly believe Jasper Therapeutics is more favorable than Actuate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jasper Therapeutics
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
Actuate Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

79.9% of Jasper Therapeutics shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 1 articles in the media. Actuate Therapeutics' average media sentiment score of 1.89 beat Jasper Therapeutics' score of 1.87 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Jasper Therapeutics Very Positive
Actuate Therapeutics Very Positive

Actuate Therapeutics' return on equity of -430.93% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A -613.51% -162.52%
Actuate Therapeutics N/A -430.93%-180.86%

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/A-$75.80M-$3.23N/A
Actuate TherapeuticsN/AN/A-$22.23M-$0.97N/A

Summary

Jasper Therapeutics beats Actuate Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Jasper Therapeutics compare to InterCure?

Jasper Therapeutics (NASDAQ:JSPR) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jasper Therapeutics currently has a consensus target price of $13.14, indicating a potential upside of 3,754.21%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Jasper Therapeutics is more favorable than InterCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jasper Therapeutics
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33
InterCure
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Jasper Therapeutics has a beta of 3, meaning that its stock price is 200% more volatile than the broader market. Comparatively, InterCure has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

InterCure has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/A-$75.80M-$3.23N/A
InterCure$78.47M0.72-$10.37M$0.0334.23

In the previous week, InterCure had 3 more articles in the media than Jasper Therapeutics. MarketBeat recorded 4 mentions for InterCure and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.87 beat InterCure's score of 0.72 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Jasper Therapeutics Very Positive
InterCure Positive

InterCure's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A -613.51% -162.52%
InterCure N/A N/A N/A

Summary

Jasper Therapeutics and InterCure tied by winning 7 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Incannex Healthcare has higher revenue and earnings than Jasper Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incannex Healthcare$90K459.52-$46.88M-$1.55N/A
Jasper TherapeuticsN/AN/A-$75.80M-$3.23N/A

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 420.98%. Jasper Therapeutics has a consensus target price of $13.14, suggesting a potential upside of 3,754.21%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Incannex Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Jasper Therapeutics
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Incannex Healthcare had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Incannex Healthcare and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.87 beat Incannex Healthcare's score of 0.93 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Incannex Healthcare Positive
Jasper Therapeutics Very Positive

Incannex Healthcare has a beta of 7, suggesting that its stock price is 600% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3, suggesting that its stock price is 200% more volatile than the broader market.

Incannex Healthcare's return on equity of -81.01% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Incannex HealthcareN/A -81.01% -76.11%
Jasper Therapeutics N/A -613.51%-162.52%

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 2.3% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Incannex Healthcare and Jasper Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPR vs. The Competition

Export
MetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.55M$3.62B$6.81B$12.20B
Dividend YieldN/A2.27%2.68%5.90%
P/E Ratio-0.1121.7825.7824.19
Price / SalesN/A327.48554.36100.04
Price / CashN/A134.9146.3353.91
Price / Book2.278.3410.766.36
Net Income-$75.80M$23.91M$3.57B$337.69M
7 Day Performance-24.72%7.15%3.20%-0.32%
1 Month Performance-62.63%5.75%2.36%0.33%
1 Year Performance-94.01%62.49%33.28%26.88%

Jasper Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JSPR
Jasper Therapeutics
3.6742 of 5 stars		$0.35
-21.8%		$13.14
+3,696.3%		-92.1%$9.69MN/AN/A20
KALA
KALA BIO
3.3371 of 5 stars		$2.64
+0.4%		$1,018.75
+38,489.0%		-98.9%$48.89MN/AN/A30
MREO
Mereo BioPharma Group
3.7141 of 5 stars		$0.30
-3.0%		$3.25
+998.0%		-89.2%$48.68M$500KN/A40
ACTU
Actuate Therapeutics
2.8018 of 5 stars		$2.05
+1.5%		$17.50
+753.7%		-69.6%$48.33MN/AN/A10
INCR
InterCure
0.7633 of 5 stars		$0.96
+9.4%		N/A-30.4%$47.79M$78.47M31.87350

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
Solar is dead. Here’s what replaces it.
Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold Will Hit $4,900
JPMorgan now sees gold hitting $4,900, and central banks are buying at a record 710 tonnes per quarter. Trump'...
Investors Alley | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel